Softbank, Amgen-Backed Neumora Therapeutics Unveils Plans For Three Phase 3 Studies For Major Depressive Disorder

Neumora Therapeutics unveiled plans for three late-stage studies for its major depressive disorder (MDD) candidate Navacaprant.

The U.S.-based clinical-stage biopharmaceutical is backed by Softbank Group Corp SFTBY SFTBF and Amgen Inc AMGN via a $100 million equity investment.

Neumora's KOASTAL Phase 3 program, comprising three Phase 3 studies, is designed to evaluate 80 mg of the once-daily navacaprant (NMRA-140) oral monotherapy for MDD. 

The U.S. trial, the KOASTAL-1 study, is expected to be initiated in 3Q23, with the KOASTAL-2 study in U.S., Canada, and Latin America in Q4 2023 and the KOASTAL-3 study in 1Q24. The study will be conducted in the U.S., Asia Pacific, and Europe. 

The planned initiation follows the successful completion of an End-of-Phase 2 meeting with the FDA and a robust Phase 2 study with navacaprant. 

The experimental drug navacaprant helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in a mid-stage trial.

Neumora's navacaprant reported drops of 3.0 at week four and 2.8 at week eight on the 17-item Hamilton Rating Scale for Depression, with p-values of 0.015 and 0.037, respectively, for moderate-to-severe patients.

Neumora hired Henry Gosebruch as president and CEO. Gosebruch, AbbVie Inc's former chief strategy officer, succeeds Paul Berns, who transitioned to executive chair.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!